Marc A. Began - 10 Aug 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: EVP & General Counsel
Issuer ticker: AXGN
Reported as of: 10 Aug 2026
Net transaction value: -$3,195,788
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:13:23 UTC
Prior SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Began

Key filing fact

Marc A. Began filed Form 4 for Axogen, Inc. (AXGN) on 12 Aug 2026.

Key facts

This page summarizes Marc A. Began's Form 4 filing for Axogen, Inc. (AXGN).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Aug 2026, 16:13.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: -$3,195,788.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821352 Primary reporting owner

Began Marc A

Relationship: EVP & General Counsel
Address: 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA
Signature: /s/ Marc Began
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +67,500
Change %: +135%
Price: $8.16^*
Shares after: 117,635
Date: 10 Aug 2026
Ownership: Direct

AXGN transaction

Common Stock

Sale

Transaction value: $3,195,788
Shares: -67,500
Change %: -57%
Price: $47.34
Shares after: 50,135
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -67,500
Change %: -75%
Price: $0.000000^*
Shares after: 22,500
Date: 10 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,500
Exercise price: $8.16
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.

Footnote F2

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F3

All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.